Senior Advisor 2 for the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative to act as Subject Matter Expert (SME) with Pharmaceutical Development and Pain Expertise
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
OMAS STRATEGIC BUYING CENTER - PROFESSIONAL SERVICES
Contract Value
Not provided
Codes & Classification
Solicitation Number
7571PSQ00012
NAICS
541690 - Other Scientific and Technical Consulting Services
Classification Code
R499
Additional Details
The Office of the Assistant Secretary for Financial Resources (ASFR), under the Department of Health and Human Services (HHS), through its OMAS Strategic Buying Center - Professional Services, has issued a combined synopsis/solicitation (Solicitation Number: 7571PSQ00012) for the procurement of a Senior Advisor 2 to support the NIH Helping to End Addiction Long-term (HEAL) Initiative. This opportunity is specifically set aside for small business concerns under NAICS code 541690 (Other Scientific and Technical Consulting Services), with a small business size standard of $19 million. The place of performance is Bethesda, Maryland.
**Purpose and Scope**
The primary objective of this procurement is to secure the services of an executive-level subject matter expert (SME) in pharmaceutical development and pain, who will serve as Senior Advisor 2 for the NIH HEAL Initiative. The HEAL Initiative is a trans-agency effort aimed at accelerating scientific solutions to address the national opioid public health crisis. The selected advisor will provide high-level feedback and technical guidance to NIH program leadership, particularly within the National Institute of Neurological Disorders and Stroke (NINDS) HEAL portfolio, focusing on drug discovery and development projects related to pain and pharmacology.
**Key Requirements and Deliverables**
The contractor will be expected to:
- Serve as a member of the HEAL External Oversight Committee, offering strategic guidance on HEAL projects and, as needed, on other NIH drug discovery and development programs.
- Provide expert feedback and technical direction on drug discovery and development initiatives, leveraging extensive experience in pharmacology and pain management.
- Engage with NIH leadership and contribute to the strategic direction of the HEAL portfolio.
Offerors must demonstrate the qualifications of proposed key personnel, particularly their expertise in drug discovery, development, and pain. Submissions must include detailed resumes, letters of commitment, and a narrative explaining how the proposed personnel meet the evaluation criteria. All key personnel must be employed by the offeror by the contract start date.
**Contract Structure and Period of Performance**
The government anticipates awarding a fixed-price purchase order with a base period of performance from November 5, 2026, to November 4, 2027, and two option years extending through November 4, 2029. The contract may not exceed three years in total duration. The estimated level of effort is 50 labor hours per year, with the possibility of an additional 50 hours annually. The contract also allows for up to $2,000 in reimbursable travel expenses per consultant per year, subject to government approval.
**Evaluation Criteria**
Quotations will be evaluated based on:
- Technical capability, with a focus on personnel qualifications.
- Price, including a completed price template and narrative.
- Past performance, with 1-2 relevant examples demonstrating similar work in complexity and magnitude.
**Submission Instructions and Compliance**
Responses are limited to ten single-sided pages (excluding resumes, letters of commitment, certifications, and the price template) and must include:
- Company name and address
- Unique Entity ID (UEI) from SAM.gov
- Authorized contact information
- Taxpayer Identification Number (TIN)
- Certification of business size
Offerors must be actively registered in the System for Award Management (SAM) at the time of submission. All required materials must be submitted electronically to Dave Romley ([email protected]) by 12:00 PM Eastern Time on November 3, 2026. Questions regarding the solicitation are due by October 29, 2026, at 12:00 PM EST.
**Contractual and Regulatory Considerations**
This solicitation incorporates numerous FAR and HHSAR provisions and clauses by reference, including requirements for key personnel, information security, and accessibility. Notably, the contract includes a salary rate limitation, prohibiting the use of NIH funds to pay direct annual salaries above the Executive Schedule, Level II rate. The contract also contains standard clauses regarding options for increased quantity and extension of the contract term.
**Contact Information**
- Primary Contact: Dave Romley, Contract Specialist, [email protected]
- Secondary Contact: Michelle Cecilia, [email protected], 301-272-9118
**Summary**
This opportunity is well-suited for small businesses with demonstrated expertise in pharmaceutical development, pain management, and high-level scientific consulting. The successful contractor will play a pivotal role in shaping the NIH HEAL Initiative’s approach to addressing the opioid crisis, providing strategic and technical guidance at the highest levels. Interested parties should ensure compliance with all submission requirements and be prepared to demonstrate both technical excellence and relevant past performance.
Documents6